Stockreport

Lineage Cell Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Lineage Cell Therapeutics, Inc.  (LCTX) 
PDF 24 Month Visual Acuity Benefits from a Single Administration with OpRegen® Reported at 2024 Retinal Cell & Gene Therapy Innovation SummitSupported OpRegen for Geographic [Read more]